Nanoligent Analysis

Precision medicines through advanced nanobiotechnology

Develop targeted cancer therapies for improved patient outcomes; Engineer protein conjugates for precise drug delivery; Conduct research to advance biomedicine knowledge; Collaborate with partners for innovative therapeutic solutions; Create affordable cancer treatments with high social impact.

Founded in 2017 by experts in nanobiotechnology; Spin-off from Universitat Autònoma de Barcelona and Institut de Recerca de l’Hospital de la Santa Creu I Sant Pau; Funded by the European Union – NextGenerationEU.

Main Information

• Information: Nanoligent is a preclinical-stage biotech company based in Barcelona, focused on developing precision nanomedicines designed to selectively target and eliminate tumor cells that overexpress the CXCR4 receptor. The company is currently raising capital to advance its lead candidate into clinical trials.
• Interests: Artificial Intelligence, Big Data/Analytics, Health/Fitness/Wellbeing, Manufacturing and Industry 4.0.
• Location: Hall 8.1 - 4YFN Stand 8.1C42.5.
• Whether tagged as startup: Yes, Nanoligent is tagged as a startup.

Contact & Links

• LinkedIn: Connect on LinkedIn
• Twitter: Not available.
• Phone Number: Not available.
• Email: Email (link to email).

Key Information

• Growth Stage: Series A.
• Country: Spain.
• Founding Year: 2017.

Company Context

• Company Name: Nanoligent
• Company Website: https://www.nanoligent.com/